Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 6/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 4/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597709 | 0.88 | RAB9A (0.50) | EPHX1CYP3A4GAACYP2C19KCNJ6 | |
| SCHEMBL5597942 | 0.88 | TP53 (0.47) | EPHX1KCNJ6KCNJ3KCNJ5MEN1 | |
| SCHEMBL5597514 | 0.86 | TRPV1 (0.44) | KCNJ6KCNJ3KCNJ5GRIK1MEN1 | |
| SCHEMBL5597553 | 0.85 | MAPT (0.51) | EPHX1CYP3A4GAACYP2C19MEN1 | |
| SCHEMBL5597539 | 0.84 | KMT2A (0.55) | MEN1KMT2A | |
| SCHEMBL5597734 | 0.84 | ALDH1A1 (0.41) | CYP3A4GAACYP2C19KCNJ6KCNJ3 | |
| SCHEMBL5597916 | 0.83 | EPHX2 (0.47) | ALDH1A1MAPTHSD17B10EPHX2 | |
| SCHEMBL5597454 | 0.82 | ALDH1A1 (0.52) | EPHX1CYP3A4GAACYP2C19KCNJ6 | |
| SCHEMBL4122716 | 0.82 | MAPT (0.46) | GAAKCNJ6KCNJ3MEN1ALDH1A1 | |
| SCHEMBL5597817 | 0.81 | MEN1 (0.43) | GAAKCNJ6KCNJ3KCNJ5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | claimed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | claimed |
| JP-2003507328-A | — | — | 2003-02-25 | — | — | JP | claimed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | claimed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | claimed |
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | disclosed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | disclosed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | disclosed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | disclosed |